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Background: Higher sunlight exposure is correlated with lower incidence of breast cancer in ecological studies, but
findings from prospective studies regarding the association of circulating levels of vitamin D with the risk of breast
cancer have been null. The objective of this study was to examine the relation between plasma levels of vitamin D
and the risk of postmenopausal breast cancer.
Methods: We conducted a nested case–control study within the Multiethnic Cohort Study of five race/ethnic
groups (white, African-American, Native Hawaiian, Japanese, and Latino) from Hawaii and Los Angeles between
2001 and 2006. Pre-diagnostic plasma levels of 25-hydroxyvitamin D2 [25(OH)D2], 25-hydroxyvitamin D3 [25(OH)D3]
and 25(OH)D (sum of 25(OH)D2 and 25(OH)D3) were examined among 707 postmenopausal breast cancer cases
and matched controls.
Results: Using conditional logistic regression models, 20 ng/mL increases of plasma 25(OH)D3 (odds ratio (OR) 0.28;
95% confidence interval (CI) 0.14-0.56) and 25(OH)D (OR 0.43; 95% CI 0.23-0.80) were inversely associated with
breast cancer risk among white women, but not among women in other race/ethnic groups. Using two-
segmented, piecewise-linear logistic regression models, the change-points of the ORs, either for 25(OH)D3 or for 25
(OH)D, were detected as 20 ng/mL among whites.
Conclusions: Circulating 25(OH)D3 and 25(OH)D were associated with a reduced risk of postmenopausal breast
cancer among whites, but not in other ethnic groups, who reside in low latitude regions.
Keywords: Breast cancer, 25-Hydroxyvitamin D3, 25-Hydroxyvitamin D2, Ethnic groups, Nested case–control studyBackground
Ecological studies reporting a correlation between lower
solar ultraviolet-B exposure and higher breast cancer in-
cidence and/or mortality [1-3] contributed to the hy-
pothesis that vitamin D may reduce breast cancer risk
[4]. Results from retrospective case–control studies are* Correspondence: marc.goodman@cshs.org
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stated.also suggestive of an inverse association of vitamin D in-
take [5] and circulating 25-hydroxyvitamin D (25(OH)D)
[6-8] with the risk of breast cancer. However, results from
cohort studies [9-16] and intervention trials [17,18] of the
association of circulating vitamin D with breast cancer in-
cidence have been generally null [7,8].
Epidemiological studies of the association of vitamin D
with disease are complicated because circulating vitamin
D levels are determined by a variety of factors, including
ultraviolet radiation exposure, skin sensitivity to sun ex-
posure, and diet [19-22]. Most investigations examining
vitamin D and breast cancer risk have been conducted. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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most reliable indicator of vitamin D status, are known to
differ substantially between race/ethnic groups with varying
diets and ability to synthesize vitamin D in the skin [19,21,23].
Among several forms of vitamin D, the two major forms
are vitamin D3 (cholecalciferol) and vitamin D2 (ergocal-
ciferol). Vitamin D3 is synthesized mostly from the irradi-
ation of 7-hydrocholesterol on the skin and only a few
foods naturally contain vitamin D3. In contrast, vitamin
D2, at lower circulating levels than vitamin D3, is obtained
from intake of foods, fortified products, and supplements.
Since skin color is a determinant of synthesis to vitamin
D3, it is important to examine the potential modifying in-
fluence of race/ethnicity on the relation of circulating vita-
min D to disease risk. Specifically, it is unknown whether
25-hydroxyvitamin D2 (25(OH)D2) interacts with race/
ethnicity on the association of vitamin D with breast can-
cer risk.
It is plausible that the association of plasma 25-hydroxy-
vitamin D3 25(OH)D3 and 25(OH)D with breast cancer
risk is non-linear, and a minimum threshold is needed for
vitamin D to exert a protective effect [5]. In this regard,
the lower cutoff values that classify vitamin D levels as in-
adequate or deficient, recently suggested by the Institute
of Medicine [24,25] and the Endocrine Society [26], were
determined based on previous studies of skeletal health,
the results of which may not be directly relevant to breast
cancer risk.
We conducted a nested case–control study within the
Multiethnic Cohort (MEC) in Hawaii and Los Angeles
to test the hypothesis that pre-diagnostic plasma levels
of 25(OH)D2 and 25(OH)D3 are associated with the risk
of postmenopausal breast cancer, and that this associ-
ation varies by race/ethnic group in populations with
relatively high year-round levels of sunlight.
Methods
The MEC is a prospective study of more than 215,000
adults from five race/ethnic groups (white, African-
American, Native Hawaiian, Japanese, Latino) in Hawaii
and Los Angeles that was established between 1993 and
1996 to examine the association of lifestyle and genes with
chronic disease risk [27]. A biospecimen repository was
developed within the MEC between 2001 and 2006 in-
cluding 36,458 postmenopausal women, ages 45–75 years,
who agreed to provide blood specimens and a short inter-
view. The MEC was approved by the Institutional Review
Boards of the University of Hawaii and the University of
Southern California.
Incident invasive breast cancer cases were identified by
linkage to the Surveillance, Epidemiology, and End Results
Program registries in the states of Hawaii and California
through October, 2010, including 729 eligible postmeno-
pausal women with a diagnosis of invasive breast cancer.Controls who were alive and free of breast cancer were
randomly selected from the pool of postmenopausal
women in the biospecimen repository and matched 1:1 to
each case within strata of geographic location (Hawaii or
California), race/ethnicity, birth year (±1 y), date of blood
draw (±6 mo), time of blood draw (±2 h), hours fasting
prior to blood draw (0- < 6, 6- < 8, 8- < 10, and ≥10 h), and
hormone replacement therapy use (HRT; as current versus
not current). Matched pairs that included a case or control
with 25(OH)D2 or 25(OH)D3 measurements below the
limits of detection (10 cases and 10 controls), or outliers
(higher levels than three standard deviation (3 cases for 25
(OH)D2, none for 25(OH)D3)), were excluded. After ex-
clusion, 707 matched sets remained for statistical analysis.
Plasma levels of 25(OH)D2 and 25(OH)D3 were analyzed
by isotope dilution liquid chromatography orbitrap mass
spectrometry (Laboratory of AAF, ThermoFisher Scientific,
Waltham, MA). The assay was validated by the Vitamin
D External Quality Assessment Scheme (DEQAS) and
National Institute of Standards and Technology (NIST)
quality assurance programs. Intra- and inter-assay vari-
ability coefficients of variations of 25(OH)D which was
the sum of 25(OH)D2 and 25(OH)D3, were 6.8% and
7.4%, based on the analysis of 47 duplicate and 23 tripli-
cate samples.
Conditional logistic regression with matched sets as strata
was used to compute odds ratios (ORs) and 95% confidence
intervals (CIs). Levels of 25(OH)D2 were coded as a binary
variable (0, >0 ng/mL) because the detection level of 25
(OH)D2 was low. For 25(OH)D3 and 25(OH)D, we used
continuous variables (10 ng/mL and 20 ng/mL) to facilitate
comparison with our results and results from the latest
meta-analyses [7,8]. For 25(OH)D, binary variables using
several cutoffs (16, 20, and 30 ng/mL) were also used based
on the recent definition of vitamin D deficiency or insuffi-
ciency [25,26]. Heterogeneity of effect across race/ethnic
groups was tested by the Wald test of the cross-product
terms for vitamin D and ethnic group. All statistical models
were adjusted for potential confounders, including body
mass index (<25.0, 25.0-29.9, ≥30.0 kg/m2), number of live
births (never, 1, 2–3, ≥4, missing), family history of breast
cancer (yes, no, missing), use of multivitamin and calcium
supplements (yes: taken at least once a week in the last year
preceding blood draw; no; missing), season (October to
March, April to September), sunburn history (yes, no, miss-
ing), and engagement in strenuous sports (never, ≤1 h/
week, >1 h/week, missing). The study participants were
queried about the frequency and duration of intake of cal-
cium supplements regardless of alone or in combination
with vitamin D.
Sensitivity analyses for 25(OH)D3 and 25(OH)D were
performed among whites by excluding women (by case–
control pair) within 6 months, one, two, three, and four
years from the date of blood draw. To find the change-
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and 25(OH)D on breast cancer risk, we implemented a
two-segmented piecewise-linear logistic regression for
each race/ethnic group [28].
Results
The mean age of the study subjects was 67.8 years
(Table 1) and the mean time between the date of blood
draw and the date of breast cancer diagnosis was 3.1 years.
Compared to controls, in all five race/ethnic groups, cases
were likely to be overweight and obese or to have a family
history of breast cancer. Dietary and supplementary intake
for energy, vitamin D and calcium was not different be-
tween cases and controls in every race/ethnic group.
Among controls, the mean plasma 25(OH)D2 levels were
the highest among African-Americans and Japanese,
and the lowest among whites. In contrast, mean plasma
25(OH)D3 and 25(OH)D levels were the highest among
whites and the lowest among African-Americans.
Plasma concentrations of 25(OH)D2 were inversely asso-
ciated with breast cancer risk among African-American
women (>0 ng/mL vs 0 ng/mL: OR 0.29; 95% CI 0.12-
0.70), but not among women in other race/ethnic groups
(Table 2). A unit increase of 20 ng/mL in plasma concen-
trations of 25(OH)D3 (OR 0.28; 95% CI 0.14-0.56) was in-
versely associated with postmenopausal breast cancer risk
among white women, but not among women in other
race/ethnic groups (test for heterogeneity, P = 0.007).
Among whites, plasma levels of 25(OH)D considered defi-
cient (<20 ng/ml) led to a 7.5 times greater risk of breast
cancer (95% CI 1.41-39.8) compared to women with circu-
lating levels of 25(OH)D at 20 ng/mL or more. For women
other than non-Hispanic whites, the association of plasma
25(OH)D levels with breast cancer risk was not statisti-
cally significant.
Among whites, results from a two-segmented piecewise-
linear logistic regression yielded a threshold at 19.4 ng/mL
for 25(OH)D3 (for unit increase in 25(OH)D3, OR 1.11,
95% CI: 0.98-1.25 below the change-point; OR 0.96, 95%
CI: 0.92-0.99 above the change-point; test for heterogen-
eity P = 0.007) and at 19.5 ng/mL for 25(OH)D (for unit
increase in 25(OH)D, OR 1.20, 95% CI: 0.97-1.48) below
the change-point; OR 0.98, 95% CI: 0.95-1.01 above the
change-point; test for heterogeneity P = 0.046) (data not
shown). Change-points, either for 25(OH)D3 or for 25
(OH)D, were not detected among African-American,
Native Hawaiian, Japanese, or Latino women.
In sensitivity analyses, no heterogeneity by length of
follow-up time after blood draw was detected in the risk
estimates by a unit increase of 20 ng/mL of plasma 25
(OH)D3 or of plasma 25(OH)D concentrations for post-
menopausal breast cancer among whites (test for hetero-
geneity P = 0.939 for 25(OH)D3; P = 0.265 for 25(OH)D)
(data not shown).Discussion
Results from this study add to the growing debate regard-
ing the potential beneficial effects of vitamin D against
breast cancer and other malignancies [29,30]. Higher cir-
culating vitamin D3 and vitamin D levels were associated
with a lower risk of postmenopausal breast cancer among
white women whose circulating 25(OH)D3 and 25(OH)D
levels exceeded those of women in other race/ethnic
groups.
Vitamin D3, which is the major form of vitamin D, is
obtained from the diet or through synthesis in the skin
from the action of ultraviolet radiation [31]. The inverse
association found in this analysis among white women
may be explained by the relatively high levels of circulating
vitamin D3 achievable among whites living in Los Angeles
and Hawaii where ambient levels of ultraviolet radiation
are sufficiently elevated throughout the year for adequate
cutaneous vitamin D production. White women in our
study had higher plasma 25(OH)D levels (means of
34.9 ng/mL in cases and of 37.4 in controls) compared to
white women in previous nested case–control studies,
with ranges from 20.0 to 31.5 ng/mL among cases and
20.4 to 33.1 ng/mL among controls [9-15,17,18]. This ob-
servation is consistent with findings from prospective
studies of dietary vitamin D, sun exposure, and breast can-
cer risk in France [32] and in the United States [33] which
showed a lower risk of breast cancer among women who
were high dietary vitamin D consumers living in southern
regions, but not in northern regions, of these countries.
A meta-analysis of studies measuring plasma 25(OH)D
levels and breast cancer risk reported a lower risk of
breast cancer associated with a 10 ng/mL increase [7] or
20 ng/mL increase [8] in pooled estimates; however,
when the pooled analysis was restricted to prospective
studies, this association was null. Our data support the
hypothesis that a minimum threshold level of 25(OH)D
exceeding 20 ng/ml is necessary for an inverse association
with postmenopausal breast cancer risk to be measurable,
although the modest number of subjects below this
threshold was a concern. A threshold effect rather than a
dose-dependent effect of vitamin D with breast cancer risk
was recently supported by a re-analysis of data from the
Women's Health Initiative [34]: the beneficial effect of
vitamin D on reducing breast cancer was examined among
women who were not using calcium or vitamin D supple-
ments at baseline, while higher doses of vitamin D did not
further decrease breast cancer incidence among women
who were using supplements at baseline.
To our knowledge, this is the first case–control study
nested in a prospective cohort that examined the associ-
ation between circulating vitamin D3 and vitamin D (sum
of vitamin D2 vitamin D3) concentrations and breast can-
cer risk in a multiethnic population. Our finding that
white women had the highest circulating vitamin D3 and/
Table 1 Basic characteristics of postmenopausal breast cancer cases and controls by race/ethnicity
White African-American Native Hawaiian Japanese Latino
(n = 294) (n = 212) (n = 136) (n = 508) (n = 264)
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
Area
Hawaii 137 93.2 137 93.2 68 100.0 68 100.0 215 84.6 215 84.6
LA 10 6.8 10 6.8 106 100.0 106 100.0 39 15.4 39 15.4 132 100.0 132 100.0
Season
Oct-Mar 65 44.2 68 46.3 54 50.9 57 53.8 38 55.9 36 52.9 98 38.6 119 46.8 70 53.0 57 43.2
Apr-Sep 82 55.8 79 53.7 52 49.1 49 46.2 30 44.1 32 47.1 156 61.4 135 53.2 62 47.0 75 56.8
Sunburn history 103 70.1 98 67.1 17 16.2 9 9.0 21 31.3 23 33.8 48 19.0 54 21.4 40 32.3 28 22.8
Family history of breast cancer 22 15.0 13 8.8 21 19.8 22 20.8 12 17.6 10 14.7 38 15.0 28 11.0 15 11.4 8 6.1
Use of multivitamins 82 56.6 73 50.3 59 56.7 56 55.4 36 52.9 33 49.3 135 53.4 126 50.0 63 48.8 69 52.7
Use of calcium supplements 68 47.9 62 43.4 29 29.9 38 36.9 18 26.5 28 43.1 114 45.8 139 55.6 52 42.3 48 38.4
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age 68.5 7.9 68.4 7.7 69.1 7.6 69.2 7.5 65.7 6.8 65.8 6.8 67.8 7.7 67.8 7.7 67.3 6.7 67.3 6.8
Body mass index (kg/m2) 25.0 4.5 24.5 5.4 28.0 5.0 28.4 5.7 27.8 5.5 28.1 6.2 24.2 4.2 23.3 3.8 28.2 5.7 27.3 5.6
Live births 2.3 1.6 2.7 1.6 2.9 1.8 2.9 2.0 3.5 2.0 3.5 1.7 2.2 1.4 2.3 1.4 3.5 2.0 4.1 2.0
Sports activity (hour/week) 0.2 0.3 0.2 0.5 0.1 0.3 0.1 0.2 0.2 0.7 0.2 0.4 0.1 0.3 0.1 0.2 0.1 0.4 0.1 0.4
Energy intake, Kcal/day 1,799 649 1,785 714 1,848 1,043 1,834 1,010 2,295 1,191 2,031 1,092 1,814 670 1,900 658 2,189 1,199 2,222 1,369
Vitamin D, IU/1000 Kcal/day 78 44 81 52 74 52 70 52 74 47 81 56 62 38 61 36 72 44 70 58
Calcium, mg/1000 Kcal/day 438 136 436 144 400 146 384 145 361 140 371 170 336 108 331 109 467 142 463 164
Phosphorus, mg/1000 Kcal/day 650 123 658 122 651 137 631 129 578 124 604 139 580 101 568 104 687 127 699 144
Plasma 25(OH)D2, ng/mL
a 3.5 5.4 2.6 4.7 2.2 5.0 3.3 5.5 1.7 3.8 2.8 5.3 4.3 5.7 3.3 4.9 2.5 4.5 3.0 5.4
Plasma 25(OH)D3, ng/mL
a 31.4 10.1 34.8 10.1 23.5 12.3 23.1 9.6 30.9 9.5 30.6 11.6 28.5 9.4 29.3 10.5 25.2 8.1 24.1 8.5
Plasma 25(OH)D, ng/mLa 34.9 10.2 37.4 9.7 25.7 12.1 26.4 11.3 32.6 8.7 33.4 12.2 32.7 9.3 32.6 10.2 27.7 9.4 27.1 9.4
Abbreviation: SD standard deviation, 25(OH)D2 25-hydroxyvitamin D2, 25(OH)D3 25-hydroxyvitamin D3, 25(OH)D sum of 25(OH)D2 and 25(OH)D3.

















Table 2 Odds ratio (OR) and 95% confidence intervals (CI) for breast cancer by categories in circulating 25(OH)D2, 25(OH)D3, and 25(OH)D levels by race/ethnicity
a
White African-American Native Hawaiian Japanese Latino Test for






OR 95% CI No.
cases/
controls
OR 95% CI No.
cases/
controls
OR 95% CI No.
cases/
controls
OR 95% CI No.
cases/
controls
OR 95% CI Overall Whites
vs. others
25(OH)D2
0 ng/mL 80/90 1.00 85/66 1.00 49/43 1.00 124/139 1.00 84/83 1.00
> 0 ng/mL 67/57 1.29 0.75 2.23 21/40 0.29 0.12 0.70 19/25 0.46 0.16 1.34 130/115 1.32 0.90 1.93 48/49 0.85 0.46 1.56 P = 0.817 P = 0.124
25(OH)D3
10 ng/mL increase 147/147 0.53 0.37 0.75 106/106 1.27 0.91 1.76 118/118 0.89 0.59 1.34 229/229 0.92 0.75 1.12 232/232 1.29 0.87 1.89 P = 0.059 P = 0.007
20 ng/mL increase 147/147 0.28 0.14 0.56 106/106 1.61 0.83 3.11 118/118 0.80 0.35 1.79 229/229 0.84 0.57 1.24 232/232 1.65 0.76 3.57
25(OH)D
10 ng/mL increase 147/147 0.66 0.48 0.90 106/106 1.08 0.79 1.47 118/118 0.79 0.52 1.20 229/229 1.04 0.84 1.28 232/232 1.17 0.84 1.64 P = 0.086 P = 0.051
20 ng/mL increase 147/147 0.43 0.23 0.80 106/106 1.16 0.63 2.16 118/118 0.63 0.27 1.45 229/229 1.08 0.71 1.65 232/232 1.38 0.71 2.69
Vitamin D deficiency
Cutoff at 16 ng/mL
≥16 ng/mL 144/146 1.00 79/85 1.00 65/64 1.00 246/245 1.00 119/119 1.00
<16 ng/mL 3/1 4.98 0.40 62.1 27/21 1.36 0.59 3.13 3/4 1.44 0.18 11.5 8/9 0.72 0.24 2.14 13/13 1.01 0.31 3.29 P = 0.395 P = 0.465
Cutoff at 20 ng/mL
≥20 ng/mL 136/145 1.00 72/70 1.00 64/61 1.00 233/231 1.00 105/102 1.00
<20 ng/mL 11/2 7.50 1.41 39.8 34/36 0.74 0.36 1.53 4/7 0.74 0.13 4.29 21/23 0.96 0.47 1.97 27/30 0.90 0.41 1.95 P = 0.226 P = 0.023
Cutoff at 30 ng/mL
≥30 ng/mL 98/115 1.00 29/39 1.00 44/39 1.00 152/144 1.00 45/42 1.00
<30 ng/mL 49/32 2.56 1.27 5.14 77/67 1.34 0.64 2.79 24/29 0.64 0.28 1.49 102/110 0.86 0.58 1.29 87/90 0.76 0.40 1.46 P = 0.025 P = 0.026
Abbreviation: 25(OH)D2 25-hydroxyvitamin D2, 25(OH)D3 25-hydroxyvitamin D3, 25(OH)D sum of 25(OH)D2 and 25(OH)D3.
Note. Values are given in ng/mL. Multiply 2.5 to convert the values to nmol/L.
aModeled through conditional logistic regression after adjustment for season, sunburn history, body mass index, strenuous sports, number of live births, family history of breast cancer, use of multivitamin, and use of
calcium supplement.
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from previous cross-sectional studies [21,23,35-38]. One
possible explanation for the unique association of vitamin
D with breast cancer risk among white women is a poten-
tial modifying effect of this association by vitamin D re-
ceptor polymorphisms (FokI, BgII) that vary substantially
by ethnic group [39-43]. The vitamin D receptor binds the
active form of 25(OH)D (i.e., 1,25 dihydroxyvitamin D
(1,25(OH)2D)) in the nucleus of breast epithelial cells,
thereby reducing cell proliferation, and increasing cell dif-
ferentiation, autophagy and apoptosis [44]. However, it is
also possible that light skin pigmentation combined with
high sun exposure, rather than differences in vitamin D re-
ceptor polymorphisms among whites compared to other
women, account for the reduction in breast cancer risk
limited to this race/ethnic group [37,45].
In contrast to the results for vitamin D3, we found that a
modest reduction in the risk of breast cancer is associated
with higher levels of plasma vitamin D2 among African-
American women. African-Americans had the lowest plasma
25(OH)D3 among the five race/ethnic groups studied. It is
possible that the apparent ethnic-specific effect of circulating
vitamin D2 on breast cancer risk among African-American
women resulted from their relatively low levels of circulating
vitamin D3 compared to other race/ethnic groups which
may have masked a modest association of risk with vitamin
D3. Vitamin D2 (ergocalciferol) is derived from irradiation
of plants or yeast and is found in humans when ingested
from food or supplements [46]. Recent literature suggests
that the binding affinity of vitamin D2 and its metabolites
to plasma vitamin D binding protein is weaker than that of
vitamin D3 [47,48], but little is known about the physio-
logic effects or ethnic-specific potency of vitamin D2.
Plasma 25(OH)D2 levels in our study participants were gen-
erally above the assay detection limit, although it is still
possible that the association found among white women in
our study resulted from chance.
Strengths of this study include its multiethnic compos-
ition, the use of pre-diagnosed biologic samples, and a rela-
tively large number of carefully matched cases and controls.
High circulating levels of vitamin D in both cases and con-
trols may have attenuated the risk estimates, but study
power remained adequate. A further strength of our ana-
lysis was the ability to adjust for body mass index, physical
activity, as well as calcium and vitamin supplements, factors
which are correlated with circulating 25(OH)D levels [49].
Because this information was gathered using a mail survey
form, recall may have been imperfect. However, all women
included in this analysis were healthy at the time of inter-
view, so any biased responses would be non-differential and
likely to attenuate risk estimates toward the null. The num-
ber of cases and controls in each ethnic group was not suf-
ficient to stratify the analyses by geographical area and/or
by season which is a possible limitation.Conclusion
In conclusion, plasma vitamin D was inversely associated
with postmenopausal breast cancer risk among white
women who reside in latitudes where levels of ultraviolet
radiation are comparatively high. It is likely that a mini-
mum threshold of vitamin D exposure from both sun and
diet is required to achieve a reduction in breast cancer risk
among postmenopausal white women.
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